Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 4
1989 5
1990 8
1991 6
1992 9
1993 12
1994 12
1995 10
1996 10
1997 11
1998 10
1999 11
2000 22
2001 8
2002 7
2003 10
2004 9
2005 9
2006 15
2007 12
2008 18
2009 20
2010 14
2011 23
2012 18
2013 12
2014 24
2015 12
2016 8
2017 11
2018 11
2019 12
2020 12
2021 10
2022 10
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

389 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Rosenberg R, et al. JAMA Netw Open. 2019 Dec 2;2(12):e1918254. doi: 10.1001/jamanetworkopen.2019.18254. JAMA Netw Open. 2019. PMID: 31880796 Free PMC article. Clinical Trial.
OBJECTIVE: To compare treatment with the orexin receptor antagonist lemborexant with placebo and zolpidem tartrate extended release in participants with insomnia disorder. ...Six participants (4 in the zolpidem group and 2 in the lemborexant 5 mg group) reported ser …
OBJECTIVE: To compare treatment with the orexin receptor antagonist lemborexant with placebo and zolpidem tartrate extended release i …
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J. Dauvilliers Y, et al. Ann Neurol. 2020 Mar;87(3):347-356. doi: 10.1002/ana.25680. Epub 2020 Feb 5. Ann Neurol. 2020. PMID: 31953863 Clinical Trial.
METHODS: Adults (64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or 50mg), or 10mg zolpidem for 30 days. The primary efficacy outcome was the change in wake time after sleep onset from baseline to days …
METHODS: Adults (64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or 5 …
Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.
Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D. Castro LS, et al. Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20. Braz J Psychiatry. 2020. PMID: 31859791 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and efficacy of a 5 mg sublingual dose of zolpidem, compared to a 10 mg oral dose, at bedtime and "as needed" following middle-of-the-night awakenings. METHODS: Participants were randomized into an oral group (oral zolpidem 10 mg an …
OBJECTIVE: To evaluate the safety and efficacy of a 5 mg sublingual dose of zolpidem, compared to a 10 mg oral dose, at bedtime and " …
The effect of zolpidem on memory consolidation over a night of sleep.
Zhang J, Yetton B, Whitehurst LN, Naji M, Mednick SC. Zhang J, et al. Sleep. 2020 Nov 12;43(11):zsaa084. doi: 10.1093/sleep/zsaa084. Sleep. 2020. PMID: 32330272 Free PMC article. Clinical Trial.
The current study investigated the effect of zolpidem on nighttime sleep and overnight improvement of episodic memories. ...RESULTS: We showed greater memory improvement after a night of sleep with zolpidem, compared to placebo, replicating a prior nap study. Additi …
The current study investigated the effect of zolpidem on nighttime sleep and overnight improvement of episodic memories. ...RESULTS: …
The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial.
Louzada LL, Machado FV, Quintas JL, Ribeiro GA, Silva MV, Mendonça-Silva DL, Gonçalves BSB, Nóbrega OT, Camargos EF. Louzada LL, et al. Neuropsychopharmacology. 2022 Jan;47(2):570-579. doi: 10.1038/s41386-021-01191-3. Epub 2021 Oct 11. Neuropsychopharmacology. 2022. PMID: 34635802 Free PMC article. Clinical Trial.
There was a 1-point reduction in mean performance in the symbols search test among zolpidem users (95% CI: -4.1, 1.5) and an almost eight-point reduction in average scores in the digit-symbol coding test among zopiclone users (95% CI: -21.7, 6.2). In summary, short-term us …
There was a 1-point reduction in mean performance in the symbols search test among zolpidem users (95% CI: -4.1, 1.5) and an almost e …
Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Citrome L, Juday T, Frech F, Atkins N Jr. Citrome L, et al. J Clin Psychiatry. 2021 Jun 1;82:20m13795. doi: 10.4088/JCP.20m13795. J Clin Psychiatry. 2021. PMID: 34077032 Free article. Clinical Trial.
Efficacy was assessed using different categorical definitions for response, and tolerability was assessed by evaluating rates of adverse events (AEs). Direct comparisons were made with zolpidem extended release (ER), and indirect comparisons were made with other hypnotic a …
Efficacy was assessed using different categorical definitions for response, and tolerability was assessed by evaluating rates of adverse eve …
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Ufer M, et al. Sleep. 2022 Mar 14;45(3):zsab224. doi: 10.1093/sleep/zsab224. Sleep. 2022. PMID: 34480579 Clinical Trial.

RESULTS: Study validity was confirmed based on drug-liking of suvorexant and zolpidem greater than placebo applying a predefined 15-point validity margin (p < 0.0001). Drug-liking VAS Emax (mean; 95% confidence interval) of daridorexant at 50 mg (73.2; 69.0-77.5) was si

…
RESULTS: Study validity was confirmed based on drug-liking of suvorexant and zolpidem greater than placebo applying a predefined 15-p …
Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder.
Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D. Moline M, et al. J Clin Sleep Med. 2021 Jun 1;17(6):1167-1174. doi: 10.5664/jcsm.9150. J Clin Sleep Med. 2021. PMID: 33590823 Free PMC article. Clinical Trial.
METHODS: Study E2006-G000-304 (SUNRISE 1; NCT02783729) was a global, multicenter, randomized, double-blind, placebo-controlled, active comparator (zolpidem)-controlled, parallel-group study comparing 2 dose levels of lemborexant (5 mg and 10 mg). ...RESULTS: Treatment with …
METHODS: Study E2006-G000-304 (SUNRISE 1; NCT02783729) was a global, multicenter, randomized, double-blind, placebo-controlled, active compa …
Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial.
Maroo N, Hazra A, Das T. Maroo N, et al. Indian J Pharmacol. 2013 Jan-Feb;45(1):34-9. doi: 10.4103/0253-7613.106432. Indian J Pharmacol. 2013. PMID: 23543804 Free PMC article. Clinical Trial.
Although 12 treatment emergent adverse events were reported with NSF-3 and 16 with zolpidem (commonest was drowsiness in both), most were mild and no serious adverse events were encountered. CONCLUSIONS: NSF-3 is a safe and effective short-term alternative to zolpidem …
Although 12 treatment emergent adverse events were reported with NSF-3 and 16 with zolpidem (commonest was drowsiness in both), most …
Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.
Lähteenmäki R, Neuvonen PJ, Puustinen J, Vahlberg T, Partinen M, Räihä I, Kivelä SL. Lähteenmäki R, et al. Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):330-340. doi: 10.1111/bcpt.13144. Epub 2018 Dec 3. Basic Clin Pharmacol Toxicol. 2019. PMID: 30295409 Free article. Clinical Trial.
We studied perceived sleep and quality of life in 92 older (age 55-91 years) outpatients with primary insomnia before and after withdrawal from long-term use of zopiclone, zolpidem or temazepam (BZDA). BZDA was withdrawn during 1 month, during which the participants receiv …
We studied perceived sleep and quality of life in 92 older (age 55-91 years) outpatients with primary insomnia before and after withdrawal f …
389 results